POSLUMA® PET's Role in Altering Prostate Cancer Recurrence Management Discussed at ASCO GU

A recent study has shed light on the effectiveness of POSLUMA® (flotufolastat F 18), a PET imaging agent, in altering treatment plans for patients with recurrent prostate cancer. The Phase 3 SPOTLIGHT trial's sub-analysis revealed that POSLUMA imaging led to a change in management for nearly 90% of the patients involved. This suggests that the use of POSLUMA can significantly impact the clinical approach to prostate cancer recurrence.

The trial included 97 patients who underwent POSLUMA PET imaging, and the results showed that 84% tested positive for recurrent prostate cancer. Notably, in 89% of these cases, the imaging results prompted a change in the patients' treatment plans. Of these changes, 91% were classified as major, indicating a significant shift in treatment strategy.

The study also highlighted that POSLUMA imaging was instrumental in identifying the presence of cancer in patients who were being considered for watchful waiting. In 75% of the cases where the management plan shifted towards watchful waiting, the PET scan results were negative for cancer. Conversely, all patients whose treatment plans were changed from salvage therapy to non-curative systemic therapy showed distant or extrapelvic lesions that were avid for flotufolastat F 18.

POSLUMA® is a radiopharmaceutical used for PET imaging of PSMA-positive lesions in men with prostate cancer who are suspected of having metastasis or recurrence based on elevated serum PSA levels. The product has been recognized for its high affinity for PSMA, which is a protein commonly found in prostate cancer cells, and its ability to provide clinically useful information even at low PSA levels.

The study's findings were presented at the ASCO GU 2024 Genitourinary Cancers Symposium, emphasizing the potential of POSLUMA PET imaging to guide more precise and effective treatment strategies for prostate cancer patients. The imaging agent's ability to influence clinical decision-making is a significant advancement in the management of prostate cancer, particularly for those facing recurrence.

POSLUMA's impact on treatment plans was underscored by the fact that it can identify the location and extent of recurrent disease, which is crucial for physicians and their patients. The study underscored the importance of accurate imaging in managing prostate cancer, as up to 40% of patients who undergo radical prostatectomy and up to 50% of those who receive radiation therapy may develop local or distant recurrences within ten years.

The study's results are a testament to the potential of POSLUMA as a diagnostic tool in the fight against prostate cancer. By providing actionable information that can lead to major changes in treatment plans, POSLUMA is positioned to play a pivotal role in improving patient outcomes and guiding more personalized approaches to cancer care.